Sentence examples for established cost effectiveness from inspiring English sources
For Level IV (established cost effectiveness), the criteria have not been detailed yet.
Four levels of recognition are distinguished: (i) theoretically sound, (ii) probable effectiveness, (iii) established effectiveness and (iv) established cost effectiveness.
We established cost effectiveness by comparing data at the end of the project year to standard care (i.e., the state of the sample before the QIC intervention).
Four levels of recognition are distinguished inspired by the UK Medical Research Council's evaluation framework for complex interventions to improve health: (i) theoretically sound, (ii) probable effectiveness, (iii) established effectiveness, and (iv) established cost effectiveness.
Introduction of HPV screening should be based on established (cost-) effectiveness.
There is a need for establishing cost effectiveness analysis institutes in SSA to guide research involving CEA and also carry out capacity building activities.
Secondary objectives of this trial are to establish cost effectiveness in terms of Quality of Adjusted Life Years QALYY) as measured by EuroQol-5 and SF-36 and costs measured by TIC-P; and to establish improvement on pain in terms of Brief Pain inventory (BPI).
This study will establish cost effectiveness of TCCCL and then make the following products available for long term implementation: – Training module of psychiatrists and psychiatric nurses working in a specialty mental health outpatient clinic to perform TCCCL integrated depression and pain treatment, and to refer the patient back to the GP with a CL letter within 3 months.
Managed care plans have been reputed to disseminate best-practice guidelines and encourage use of preventative services with established cost-effectiveness evidence.
Orphan drugs frequently present ICER values far above established cost-effectiveness thresholds, but this is not the case with azacitidine, which has a low ICER value compared with other orphan drugs [23 28].
Even when considering clinical benefits from HAART, ignoring added costs, the cost per QALY gained remained below three times the Mexican GDP per capita, and below established cost-effectiveness thresholds.
